Discontinued — last reported Q4 '23

Business Segments · D&A

Other segment revenue — D&A

Idexx Laboratories Other segment revenue — D&A remained flat by 0.0% to $895.00K in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 6.5%, from $957.25K to $895.00K. Over 2 years (FY 2021 to FY 2023), Other segment revenue — D&A shows relatively stable performance with a -2.6% CAGR.

Analysis

StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ4 2023
Rolls up toD&A

How to read this metric

Increasing values suggest higher capital investment or shorter asset lifespans, while stable values indicate consistent capital expenditure.

Detailed definition

This metric represents the non-cash expense allocated to the 'Other' segment for the systematic allocation of the cost o...

Peer comparison

Standard metric across all industries to assess capital intensity and EBITDA adjustments.

Metric ID: idxx_segment_other_segment_revenue_depreciation_and_amortization

Historical Data

3 years
 FY'21FY'22FY'23
Value$3.78M$3.83M$3.58M
YoY Change+1.4%-6.5%
Range$3.58M$3.83M
CAGR-2.6%
Avg YoY Growth-2.6%
Median YoY Growth-2.6%

Frequently Asked Questions

What is Idexx Laboratories's other segment revenue — d&a?
Idexx Laboratories (IDXX) reported other segment revenue — d&a of $895.00K in Q4 2023.
How has Idexx Laboratories's other segment revenue — d&a changed year-over-year?
Idexx Laboratories's other segment revenue — d&a decreased by 6.5% year-over-year, from $957.25K to $895.00K.
What is the long-term trend for Idexx Laboratories's other segment revenue — d&a?
Over 2 years (2021 to 2023), Idexx Laboratories's other segment revenue — d&a has grown at a -2.6% compound annual growth rate (CAGR), from $3.78M to $3.58M.
What does other segment revenue — d&a mean?
The non-cash expense for the wear and tear or expiration of assets within the 'Other' segment.